Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder
Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above. (Source: Drug Development Technology)
Source: Drug Development Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news
AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC
AstraZeneca and Hutchison China MediTech (Chi-Med) have started a Phase III SAVOIR clinical trial of savolitinib to treat patients with papillary renal cell carcinoma (PRCC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news
M & As this week: NantCell, Shanghai No1 Pharmacy
NantCell has signed a definitive agreement to acquire Altor BioScience for a purchase consideration of approximately $290m. (Source: Drug Development Technology)
Source: Drug Development Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news
CytomX starts dosing in Phase I/II trial of CX-2009 to treat solid tumours
US-based biopharmaceutical firm CytomX Therapeutics has started dosing patients in a Phase I/II clinical trial (PROCLAIM CX-2009) of CX-2009 for the treatment of patients with select advanced solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - June 29, 2017 Category: Pharmaceuticals Source Type: news
MabVax begins dosing of MVT-1075 in Phase I cancer therapy trial
US-based biotechnology firm MabVax Therapeutics has started dosing patients in a Phase I clinical trial of MVT-1075 to treat patients with CA19-9 positive malignancies such as pancreatic, colon and lung cancers. (Source: Drug Development Technology)
Source: Drug Development Technology - June 28, 2017 Category: Pharmaceuticals Source Type: news
Genkyotex starts enrolment in Phase II trial of GKT831 to treat PBC
French company Genkyotex has started patient enrolment in a Phase II clinical trial of GKT831 for the treatment of patients with primary biliary cholangitis (PBC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 28, 2017 Category: Pharmaceuticals Source Type: news
Gemphire reports positive top-line results from Phase IIb trial of HoFH drug
US-based Gemphire Therapeutics has reported positive top-line results from a Phase IIb clinical trial (COBALT-1) of gemcabene to treat patients with homozygous familial hypercholesterolemia (HoFH). (Source: Drug Development Technology)
Source: Drug Development Technology - June 28, 2017 Category: Pharmaceuticals Source Type: news
Sitka Biopharma to initiate Phase I trial of STK-01 to treat bladder cancer
Canada-based biotechnology firm Sitka Biopharma has entered an agreement with Cancer Research UK and Cancer Research Technology (CRT) to start a Phase I clinical trial of STK-01 for treatment of patients with bladder cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 27, 2017 Category: Pharmaceuticals Source Type: news
Verona to study RPL554 in Phase IIb trial for COPD in five European countries
UK-based biopharmaceutical firm Verona Pharma has secured regulatory approval to start a Phase IIb clinical trial of RPL554 in patients with chronic obstructive pulmonary disease (COPD) in the UK, Germany, Romania, Bulgaria and the Czech Republic. (Source: Drug Development Technology)
Source: Drug Development Technology - June 27, 2017 Category: Pharmaceuticals Source Type: news
Teva and Xenon ’s Phase II trial of TV-45070 for PHN fails to meet endpoints
Teva Pharmaceutical Industries and Xenon Pharmaceuticals have reported top-line data from a Phase II clinical trial of TV-45070 to treat patients suffering from post-herpetic neuralgia (PHN), with the drug failing to meet required endpoints. (Source: Drug Development Technology)
Source: Drug Development Technology - June 27, 2017 Category: Pharmaceuticals Source Type: news
Genentech and Epizyme to study tazemetostat in Phase Ib/II combination trial for NSCLC
Roche Group ’s biotechnology subsidiary Genentech has expanded clinical collaboration with biopharmaceutical firm Epizyme to investigate the combination of atezolizumab (Tecentriq) and tazemetostat in a Phase Ib/II clinical trial to treat non-small-ce… (Source: Drug Development Technology)
Source: Drug Development Technology - June 26, 2017 Category: Pharmaceuticals Source Type: news
Durect concludes enrolment in PERSIST trial of non-opioid analgesic
US-based biopharmaceutical company Durect has concluded patient enrolment in its Phase III PERSIST clinical trial of Posimir (Saber-Bupivacaine) for pain relief following surgery. (Source: Drug Development Technology)
Source: Drug Development Technology - June 26, 2017 Category: Pharmaceuticals Source Type: news
Xenetic Biosciences enrols first patient in Phase II trial of XBIO-101 for endometrial cancer
US-based biopharmaceutical firm Xenetic Biosciences has started patient enrolment in its Phase II clinical trial of XBIO-101 (sodium cridanimod) and progestin therapy combination to treat patients with endometrial cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 26, 2017 Category: Pharmaceuticals Source Type: news
Bial and Eisai report positive results from Phase II trial of Zebinix for epilepsy
Bial and Eisai have reported a positive outcome from a Phase II clinical trial (Study 208) of Zebinix (eslicarbazepine acetate) in children with focal-onset epilepsy. (Source: Drug Development Technology)
Source: Drug Development Technology - June 25, 2017 Category: Pharmaceuticals Source Type: news
DelMar Pharma to initiate Phase III trial of VAL-083 to treat GBM
Canadian-based cancer therapies developer DelMar Pharmaceuticals is set to initiate a Phase III STAR-3 clinical trial of VAL-083 for the treatment of patients with refractory glioblastoma multiforme (GBM), following the approval from Institutional Re … (Source: Drug Development Technology)
Source: Drug Development Technology - June 25, 2017 Category: Pharmaceuticals Source Type: news
